Current strategies for targeting HPK1 in cancer and the barriers to preclinical progress
- 2 April 2024
- journal article
- research article
- Published by Taylor & Francis in Expert Opinion on Therapeutic Targets
- Vol. 28 (4) , 237-250
Abstract
Hematopoietic progenitor kinase 1 (HPK1), a 97-kDa serine/threonine Ste20-related protein kinase, functions as an intracellular negative regulator, primarily in hematopoietic lineage cells, where it regulates T cells, B cells, dendritic cells and other immune cells. Loss of HPK1 kinase activity results in exacerbated cytokine secretion, enhanced T cell signaling, improved viral clearance, and thus increased restraint of tumor growth. These findings highlight HPK1 as a promising target for immuno-oncology treatments, culminating in the advancement of candidate compounds targeting HPK1 to clinical trials by several biotech enterprises. Through searching PubMed, Espacenet-patent search, and clinicaltrials.gov, this review provides a comprehensive analysis of HPK1, encompassing its structure and roles in various downstream signaling pathways, the consequences of constitutive activation of HPK1, and potential therapeutic strategies to treat HPK1-driven malignancies. Moreover, the review outlines the patents issued for small molecule inhibitors and clinical investigations of HPK1. To enhance the success of tumor immunotherapy in clinical trials, it is important to develop protein degraders, allosteric inhibitors, and antibody-drug conjugates based on the crystal structure of HPK1, and to explore combination therapy approaches. Although several challenges remain, development of HPK1 inhibitors display promising in preclinical and clinical studies.Keywords
Funding Information
- China Postdoctoral Science Foundation (2023M732005)
This publication has 110 references indexed in Scilit:
- Design and synthesis of 1H-pyrazolo[3,4-d]pyrimidine derivatives as hematopoietic progenitor kinase 1 (HPK1) inhibitorsBioorganic Chemistry, 2023
- Discovery of diaminotriazine carboxamides as potent inhibitors of hematopoetic progenitor kinase 1Bioorganic Chemistry, 2023
- An HPK1 inhibitor enhanced the tumour response to anti-PD-1 immunotherapy in non-Hodgkin’s lymphomaClinical and Experimental Medicine, 2023
- Small molecule-based immunomodulators for cancer therapyActa Pharmaceutica Sinica B, 2022
- Molecular mechanisms of chemo‐ and radiotherapy resistance and the potential implications for cancer treatmentMedcomm, 2021
- Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint BlockadeJAMA Oncology, 2019
- Immune-Related Adverse Events Associated with Immune Checkpoint InhibitorsBioDrugs, 2016
- Germinal Center Kinase–like Kinase Overexpression in T Cells as a Novel Biomarker in Rheumatoid ArthritisArthritis & Rheumatism, 2013
- HPK1 as a novel target for cancer immunotherapyImmunologic Research, 2012
- Functional interactions of HPK1 with adaptor proteinsJournal of Cellular Biochemistry, 2005